Atlas Venture Fund X, L.P. Gemini Therapeutics, Inc. (GMTX) insider trading activity

Atlas Venture Fund X, L.P. is > 10% Shareholder of Gemini Therapeutics, Inc. . Currently has a direct ownership of 1.4 Million shares of GMTX, which is worth approximately $34.2 Million. The most recent transaction as insider was on Jan 23, 2024, when has been sold 47,500 shares (Common Stock) at a price of $67.65 per share, resulting in proceeds of $3,213,375. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.4M

0% 3M change

5.24% 12M change

Total Value Held $34.2 Million

Atlas Venture Fund X, L.P. Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 23 2024	SELL Open market or private sale	$3,213,375 $67.65 p/Share	47,500 Reduced 3.28%	1,402,186 Common Stock
Jan 10 2024	SELL Open market or private sale	$1,920,000 $64.0 p/Share	30,000 Reduced 2.03%	1,449,686 Common Stock
Dec 14 2023	SELL Open market or private sale	$1,818,983 $59.01 p/Share	30,825 Reduced 2.04%	1,479,686 Common Stock
Dec 13 2023	SELL Open market or private sale	$320,710 $60.25 p/Share	5,323 Reduced 0.35%	1,510,511 Common Stock
Dec 12 2023	SELL Open market or private sale	$4,909,353 $62.98 p/Share	77,951 Reduced 4.89%	1,515,834 Common Stock
Sep 16 2023	SELL Open market or private sale	$112,560 $53.22 p/Share	2,115 Reduced 0.13%	1,593,785 Common Stock
Sep 15 2023	SELL Open market or private sale	$13,869,125 $53.16 p/Share	260,894 Reduced 14.05%	1,595,900 Common Stock
Sep 14 2023	SELL Open market or private sale	$5,010,042 $53.05 p/Share	94,440 Reduced 4.84%	1,856,794 Common Stock
Aug 15 2023	SELL Open market or private sale	$5,820,015 $52.4 p/Share	111,069 Reduced 5.39%	1,951,234 Common Stock
Aug 14 2023	SELL Open market or private sale	$9,322,250 $53.27 p/Share	175,000 Reduced 7.82%	2,062,303 Common Stock
Dec 29 2022	BUY Other acquisition or disposition	-	1,835,799 Added 45.07%	2,237,303 Common Stock

Also insider at

GBIO

Generation Bio Co. Healthcare

> 10% Shareholder

MGTA

Magenta Therapeutics, Inc. Healthcare

> 10% Shareholder

KYMR

Kymera Therapeutics, Inc. Healthcare

IKNA

Ikena Oncology, Inc. Healthcare

> 10% Shareholder

AVF